PELL Bio-Med Technology Co (TPE:6949) Current Deferred Revenue: NT$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6949 PELL Bio-Med Technology Co Ltd TPE:6949
9 GF Score
Price NT$1,070.00
! 6 Warning Signs
View Full Analysis

What is PELL Bio-Med Technology Co Current Deferred Revenue?

PELL Bio-Med Technology Co TPE:6949 +4.90% 9 Current Deferred Revenue is NT$0.00 Mil as of Mar. 2026. GuruFocus rates TPE:6949 with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

PELL Bio-Med Technology Co's current deferred revenue for the quarter that ended in Mar. 2026 was NT$0.00 Mil.

PELL Bio-Med Technology Co Current Deferred Revenue Related Terms

PELL Bio-Med Technology Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for PELL Bio-Med Technology Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PELL Bio-Med Technology Co Current Deferred Revenue Chart

PELL Bio-Med Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.00 0.00 0.00 0.00 0.00

PELL Bio-Med Technology Co Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6949
9GF Score
PELL Bio-Med Technology Co Ltd TPE:6949
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0.00 Mil mean?
PELL Bio-Med Technology Co (TPE:6949) has a Current Deferred Revenue of NT$0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PELL Bio-Med Technology Co and its competitors.
Is PELL Bio-Med Technology Co's Current Deferred Revenue too high?
PELL Bio-Med Technology Co's current Current Deferred Revenue is NT$0.00 Mil. Overall, PELL Bio-Med Technology Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does PELL Bio-Med Technology Co's Current Deferred Revenue compare to VRTX and REGN?
PELL Bio-Med Technology Co's Current Deferred Revenue of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PELL Bio-Med Technology Co and its competitors. PELL Bio-Med Technology Co's current Current Deferred Revenue is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PELL Bio-Med Technology Co stock overvalued right now?
PELL Bio-Med Technology Co (TPE:6949) has a current Current Deferred Revenue of NT$0.00 Mil. The current Current Deferred Revenue is NT$0.00 Mil. PELL Bio-Med Technology Co's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For PELL Bio-Med Technology Co (TPE:6949), the current Current Deferred Revenue is NT$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PELL Bio-Med Technology Co Business Description

Address No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, TWN
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell). The company's segments includes Cell products, Consulting services, and Others.
9GF Score

Get the complete analysis for TPE:6949

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$1,070.00
Price